These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7364921)

  • 1. Determination of 6-diazo-5-oxo-L-norleucine in plasma and urine by reversed-phase high-performance liquid chromatography of the dansyl derivative.
    Powis G; Ames MM
    J Chromatogr; 1980 Jan; 181(1):95-9. PubMed ID: 7364921
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.
    Alt J; Potter MC; Rojas C; Slusher BS
    Anal Biochem; 2015 Apr; 474():28-34. PubMed ID: 25584882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of renal gamma-glutamyl transferase by 6-diazo-5-oxo-L-norleucylglycine, an inactive precursor of affinity-labeling reagent.
    Inoue M; Morino Y
    Proc Natl Acad Sci U S A; 1981 Jan; 78(1):46-9. PubMed ID: 6113588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).
    Rahman A; Smith FP; Luc PT; Woolley PV
    Invest New Drugs; 1985; 3(4):369-74. PubMed ID: 4086244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
    Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
    Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative.
    Powis G; Ames MM
    J Chromatogr; 1979 Feb; 170(1):195-201. PubMed ID: 544618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
    Kisner DL; Catane R; Muggia FM
    Recent Results Cancer Res; 1980; 74():258-63. PubMed ID: 7192426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport mechanisms of 6-diazo-5-oxo-L-norleucine in Escherichia coli K-12.
    Williams MV
    Microbiologica; 1982 Jan; 5(1):57-61. PubMed ID: 7050636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THE INTERACTION OF 6-DIAZO-5-OXO-L-NORLEUCINE WITH PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE.
    HARTMAN SC
    J Biol Chem; 1963 Sep; 238():3036-47. PubMed ID: 14081921
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the hydrolysis and the covalent binding of 6-diazo-5-oxo-L-[6-14C]norleucine by rat renal phosphate-dependent glutaminase.
    Clark VM; Shapiro RA; Curthoys NP
    Arch Biochem Biophys; 1982 Jan; 213(1):232-9. PubMed ID: 6120680
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of diazo-oxo-norleucine on cell kinetics and odontoblast differentiation in cultured embryonic mouse molars.
    Olive M; Ruch JV
    Arch Oral Biol; 1982; 27(6):505-11. PubMed ID: 6956264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal geometry: an alternative explanation of the effect of 6-diazo-5-oxo-l-norleucine on the development of chick cornea.
    Gordon H
    Dev Biol; 1976 Oct; 53(2):303-5. PubMed ID: 992212
    [No Abstract]   [Full Text] [Related]  

  • 13. Avian corneal innervation: inhibition of nerve ring formation by 6-diazo-5-oxo-L-norleucine.
    Bee JA; Unruh NC; Sommerfeld DL; Conrad GW
    Dev Biol; 1982 Jul; 92(1):123-32. PubMed ID: 7106373
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro cartilage formation: effects of 6-diazo-5-oxo-L-norleucine (DON) on glycosaminoglycan and collagen synthesis.
    Linsenmayer TF; Kochhar DM
    Dev Biol; 1979 Apr; 69(2):517-28. PubMed ID: 437352
    [No Abstract]   [Full Text] [Related]  

  • 15. [Inactivation of microbial glutamin-(asparagin-)ase by azaserine and 6-diazo-5-oxo-L-norleucine].
    Lebedeva ZI; Kabanova EA; Berezov TT
    Biull Eksp Biol Med; 1985 Dec; 100(12):696-8. PubMed ID: 4074870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
    Sklaroff RB; Casper ES; Magill GB; Young CW
    Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal development. V. Treatment of five-day-old embryos of domestic fowl with 6-diazo-5-oxo-L-norleucine (DON).
    Coulombre J; Coulombre A
    Dev Biol; 1975 Aug; 45(2):291-303. PubMed ID: 1193300
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
    Huber KR; Mayer EP; Mitchell DF; Roberts J
    Br J Cancer; 1987 Jun; 55(6):653-6. PubMed ID: 3620309
    [No Abstract]   [Full Text] [Related]  

  • 19. Highly sensitive HPLC method for the determination of galantamine in human plasma and urine through derivatization with dansyl chloride using fluorescence detector.
    Özdemir E; Tatar Ulu S
    Luminescence; 2017 Nov; 32(7):1145-1149. PubMed ID: 28430400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Casper E
    Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.